Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Go back to Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease| (NYSE: BHVN) | Delayed: 14.65 -0.1 (0.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.75 | 52 Week High | $ | |||
| Open | $14.65 | 52 Week Low | $ | |||
| Day High | $14.86 | P/E | N/A | |||
| Day Low | $14.35 | EPS | $ | |||
| Volume | 1,549,226 | |||||
